Accuracy of Clarius, Handheld Wireless Point-of-Care Ultrasound, in Evaluating Prostate Morphology and Volume Compared to Radical Prostatectomy Specimen Weight: Is There a Difference between Transabdominal vs Transrectal Approach?

Portable wireless ultrasound in pediatric neurosurgery: a valuable resource for developing countries

This investigation assesses the functionality, diagnostic efficacy, and limitations of a portable phased-array ultrasound apparatus in pediatric neurosurgical applications within a resource-constrained environment in Mombasa, Kenya. The ultrasound device was integrated into four neurosurgical missions conducted under the auspices of the SAWUBONA Foundation between 2021-2023. A retrospective analysis was performed on the diagnosed cases. Systematic training was provided to local neurosurgeons to enable autonomous operation of the device. Three representative cases were selected to elucidate the device's utility and constraints. The device was incorporated into the diagnostic and therapeutic regimens for 29 pediatric patients, culminating in 30 surgical interventions. Its diagnostic applicability was primarily confined to pediatric patients below one year of age, with a focus on hydrocephalus management. The apparatus consistently yielded sufficient data for discriminating between shunt placement and endoscopic third ventriculostomy. Its portability rendered it highly valuable across multiple healthcare settings, including outpatient clinics, surgical theaters, and inpatient wards. The educational initiative demonstrated a rapid learning curve among local healthcare professionals, enabling them to independently conduct examinations. The portable phased-array ultrasound device exhibited considerable diagnostic precision, particularly in the assessment and management of hydrocephalic conditions among pediatric patients within their first year of life. Its compact design and user-friendliness position it as a viable instrument for resource-limited environments and for educational enhancement in developing countries.

Surface-Based Ultrasound Scans for the Screening of Prostate Cancer

Surface-based ultrasound (SUS) systems have undergone substantial improvement over the years in image quality, ease-of-use, and reduction in size. Their ability to image organs non-invasively makes them a prime technology for the diagnosis and monitoring of various diseases and conditions. An example is the screening/risk- stratification of prostate cancer (PCa) using prostate-specific antigen density (PSAD). Current literature predominantly focuses on prostate volume (PV) estimation techniques that make use of magnetic resonance imaging (MRI) or transrectal ultrasound (TRUS) imaging, while SUS techniques are largely overlooked. If a reliable SUS PCa screening method can be introduced, patients may be able to forgo unnecessary MRI or TRUS scans. Such a screening procedure could be introduced into standard primary care settings with point-of-care ultrasound systems available at a fraction of the cost of their larger hospital counterparts. This review analyses whether literature suggests it is possible to use SUS-derived PV in the calculation of PSAD.

Measures of acromiohumeral distance with wireless ultrasound machine in subacromial impingement syndrome: an inter-machine reliability study

Aim

Shoulder pain is the third most prevalent musculoskeletal condition that impairs function. Subacromial impingement syndrome is among the most typical causes of shoulder pain. The aim of this study was to evaluate inter-machine reliability of acromiohumeral distance measurements performed with standard ultrasound and wireless ultrasound devices in patients with subacromial impingement syndrome.

Material and methods

A total of 61 participants diagnosed with subacromial impingement syndrome were included. Acromiohumeral distance was measured with wireless and standard ultrasound devices in a neutral position and at 60-degree abduction, respectively. The inter-machine intraclass correlation coefficient, standard error of measurements, and minimum detectable changes were calculated.

Results

Inter-machine reliability measured in the neutral position was excellent (ICC = 0.97, 95% CI = 0.95-0.98); the standard error of measurement was 0.23 mm, and the minimum detectable change was 0.63 mm. Inter-machine reliability measured at 60 degrees abduction was excellent as well (ICC = 0.96; 95% CI; 0.93-0.97). The standard error of measurements was 0.20 mm, and the minimum detectable change was 0.55 mm. The mean difference between the two machines was 0.04 mm for the neutral position and 0.02 mm for the 60-degree abduction position.

Conclusions

The study showed that wireless ultrasound devices were similar to standard ultrasound devices in measuring the acromiohumeral distance in patients with subacromial impingement syndrome. The findings could contribute to a significant improvement in the clinical use of wireless ultrasound devices.

Bedside Clinical Hand-held Ultrasound in an Internal Medicine Department: The "Bed Med-Us" Experience of Codogno and its Clinical Utility in the Management of Diagnosis and Therapy in 1007 Patients

Purpose Handheld ultrasound (HH-US) answers simple clinical questions in emergencies. We performed conventional US with HH-US at the patient's bedside (BED) during a medical visit (MED) (BED MED-US). The purpose of this prospective study is to estimate BED MED-US reliability, its clinical impact in helping the clinician to formulate correct diagnoses, and its ability to save time and money. Materials and Methods 1007 patients (519 M; age:76.42) were assessed (from March 2021 to November 2022) in one or more districts. Final diagnosis was determined with clinical and reference tests (chest RX/CT, abdominal CT, endoscopy, etc.). Sensitivity, specificity, LR+ and LR-, and corresponding AUROC were evaluated. HH-US diagnoses were classified as: confirmation (HH-US revealed the sonographic signs that confirmed the clinical diagnosis) (CO), exclusion (HH-US excluded the presence of the ultrasound signs of other pathologies, in the clinical differential diagnosis) (EX), etiological (HH-US reaches diagnosis in clinically doubtful cases) (ET), or clinically relevant incidental (HH-US diagnoses that change the patient's process completely) (INC). Results HH-US reliability: true-pos: 752; true-neg: 242; false-pos: 7; false-neg: 6 (sens: 99.1%, spec: 97.6%, LR+: 98.5; LR-: 00.15, AUROC: 0.997); clinical impact: CO-diagnosis: 21%; EX: 25%; ET: 47%; INC: 7%; saved time and money: approximately 35,572 minutes of work and 9324 euros. Conclusion BED MED-US is a reliable clinical imaging system, with an important clinical impact both in diagnosis (etiological in 47%, incidental in 7%) and in the management of personnel resources.

Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways

Introduction

Modern image-guided biopsy pathways at diagnostic centres have greatly refined the investigations of men referred with suspected prostate cancer. However, the referral criteria from primary care are still based on historical prostate-specific antigen (PSA) cut-offs and age-referenced thresholds. Here, we tested whether better contemporary pathways and biopsy methods had improved the predictive utility value of PSA referral thresholds.

Methods

PSA referral thresholds, age-referenced ranges and PSA density (PSAd) were assessed for positive predictive value (PPV) in detection of clinically significant prostate cancer (csPCa - histological ⩾ Grade Group 2). Data were analysed from men referred to three diagnostics centres who used multi-parametric magnetic resonance imaging (mpMRI)-guided prostate biopsies for disease characterisation. Findings were validated in a separate multicentre cohort. Results: Data from 2767 men were included in this study. The median age, PSA and PSAd were 66.4 years, 7.3 ng/mL and 0.1 ng/mL2, respectively. Biopsy detected csPCa was found in 38.7%. The overall area under the curve (AUC) for PSA was 0.68 which is similar to historical performance. A PSA threshold of ⩾ 3 ng/mL had a PPV of 40.3%, but this was age dependent (PPV: 24.8%, 32.7% and 56.8% in men 50-59 years, 60-69 years and ⩾ 70 years, respectively). Different PSA cut-offs and age-reference ranges failed to demonstrate better performance. PSAd demonstrated improved AUC (0.78 vs 0.68, p < 0.0001) and improved PPV compared to PSA. A PSAd of ⩾ 0.10 had a PPV of 48.2% and similar negative predictive value (NPV) to PSA ⩾ 3 ng/mL and out-performed PSA age-reference ranges. This improved performance was recapitulated in a separate multi-centre cohort (n = 541).

Conclusion

The introduction of MRI-based image-guided biopsy pathways does not appear to have altered PSA diagnostic test characteristics to positively detect csPCa. We find no added value to PSA age-referenced ranges, while PSAd offers better PPV and the potential for a single clinically useful threshold (⩾0.10) for all age groups.

Level of evidence

IV.

Ultrasound monitoring of microcirculation: An original study from the laboratory bench to the clinic

OBJECTIVE

Monitoring microcirculation and visualizing microvasculature are critical for providing diagnosis to medical professionals and guiding clinical interventions. Ultrasound provides a medium for monitoring and visualization; however, there are challenges due to the complex microscale geometry of the vasculature and difficulties associated with quantifying perfusion. Here, we studied established and state-of-the-art ultrasonic modalities (using six probes) to compare their detection of slow flow in small microvasculature.

METHODS

Five ultrasonic modalities were studied: grayscale, color Doppler, power Doppler, superb microvascular imaging (SMI), and microflow imaging (MFI), using six linear probes across two ultrasound scanners. Image readability was blindly scored by radiologists and quantified for evaluation. Vasculature visualization was investigated both in vitro (resolution and flow characterization) and in vivo (fingertip microvasculature detection).

RESULTS

Superb Microvascular Imaging (SMI) and Micro Flow Imaging (MFI) modalities provided superior images when compared with conventional ultrasound imaging modalities both in vitro and in vivo. The choice of probe played a significant difference in detectability. The slowest flow detected (in the lab) was 0.1885 ml/s and small microvasculature of the fingertip were visualized.

CONCLUSIONS

Our data demonstrated that SMI and MFI used with vascular probes operating at higher frequencies provided resolutions acceptable for microvasculature visualization, paving the path for future development of ultrasound devices for microcirculation monitoring.

Pocket-sized, wireless-Bluetooth ultrasound system to perform diagnostic and low-complexity interventional procedures in bedridden patients during the COVID-19 pandemic: from intensive care unit to domiciliary service?

The use of a pocked-sized, wireless-Bluetooth ultrasound portable system with display images presented on a tablet facilitated the work of our radiologists during the first wave of coronavirus disease 2019 (COVID-19) to perform diagnostic and interventional procedures in bedridden patients. The device is equipped with a battery-powered probe without cables that transmits images to a tablet (or a cell phone) through a dedicated App. We hypothesise in future to extend diagnostic and low-complexity interventional procedures from hospitalised patients to at-home patients who are not able to mobilise out of bed or are difficult to transport. This domiciliary service might also reduce the overhead of hospital accesses.

Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound

Brain tumors are particularly challenging malignancies, due to their location in a structurally and functionally distinct part of the human body - the central nervous system (CNS). The CNS is separated and protected by a unique system of brain and blood vessel cells which together prevent most bloodborne therapeutics from entering the brain tumor microenvironment (TME). Recently, great strides have been made through microbubble (MB) ultrasound contrast agents in conjunction with ultrasound energy to locally increase the permeability of brain vessels and modulate the brain TME. As we elaborate in this review, this physical method can effectively deliver a wide range of anticancer agents, including chemotherapeutics, antibodies, and nanoparticle drug conjugates across a range of preclinical brain tumors, including high grade glioma (glioblastoma), diffuse intrinsic pontine gliomas, and brain metastasis. Moreover, recent evidence suggests that this technology can promote the effective delivery of novel immunotherapeutic agents, including immune check-point inhibitors and chimeric antigen receptor T cells, among others. With early clinical studies demonstrating safety, and several Phase I/II trials testing the preclinical findings underway, this technology is making firm steps towards shaping the future treatments of primary and metastatic brain cancer. By elaborating on its key components, including ultrasound systems and MB technology, along with methods for closed-loop spatial and temporal control of MB activity, we highlight how this technology can be tuned to enable new, personalized treatment strategies for primary brain malignancies and brain metastases.